



HHS Public Access

Author manuscript

Dev Cell. Author manuscript; available in PMC 2021 May 04.

Published in final edited form as:

Dev Cell. 2020 May 04; 53(3): 358–369.e6. doi:10.1016/j.devcel.2020.03.015.

Non-Canonical Caspase Activity Antagonizes p38 MAPK Stress-Priming Function to Support Development

Benjamin P. Weaver^{1,3,4,*}, Yi M. Weaver^{1,3}, Shizue Omi², Wang Yuan¹, Jonathan J. Ewbank², Min Han³

¹Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390, USA

²Aix Marseille University, CNRS, INSERM, CIML, Turing Centre for Living Systems, Marseille, France

³Department of Molecular, Cellular and Developmental Biology, University of Colorado, Boulder and Howard Hughes Medical Institute, Boulder, CO 80309, USA

⁴Lead Contact

SUMMARY

Recent studies have revealed non-canonical activities of apoptotic caspases involving specific modulation of gene expression, such as limiting asymmetric divisions of stem-like cell types. Here we report that CED-3 caspase negatively regulates an epidermal p38 stress-responsive MAPK pathway to promote larval development in *C. elegans*. We show that PMK-1 (p38 MAPK) primes animals for encounters with hostile environments at the expense of retarding post-embryonic development. CED-3 counters this function by directly cleaving PMK-1 to promote development. Moreover, we found that CED-3 and PMK-1 oppose each other to balance developmental and stress-responsive gene expression programs. Specifically, expression of more than 300 genes is inversely regulated by CED-3 and PMK-1. Analyses of these genes showed enrichment for epidermal stress-responsive factors, including the fatty acid synthase FASN-1, anti-microbial peptides, and genes involved in lethargus states. Our findings demonstrate a non-canonical role for a caspase in promoting development by limiting epidermal stress response programs.

Graphical Abstract

*Correspondence: benjamin.weaver@utsouthwestern.edu.

AUTHOR CONTRIBUTIONS


B.P.W. and Y.M.W. conceived of research, performed experiments, and analyzed data; S.O.M. and W.Y. performed experiments; J.E. conceived of research, analyzed data, and edited the paper; B.P.W. wrote the paper; M.H. supervised the study and edited the paper.

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.devcel.2020.03.015>.

DECLARATION OF INTERESTS

The authors declare no competing interests.



In Brief

Weaver et al. describe a non-apoptotic role for CED-3 caspase during development in *C. elegans*. They show that a p38 MAPK pathway primes animals for stressful encounters by upregulating stress-responsive genes and slowing development. CED-3 antagonizes this stress response via proteolytic inactivation of p38, thus promoting development.

INTRODUCTION

Caspases are conserved proteases well known for their roles in initiating and executing apoptosis, mostly by proteolytic activation of target proteins (Conradt and Xue, 2005; Crawford and Wells, 2011). Recent studies across diverse phyla of metazoans have reported non-apoptotic functions for several apoptotic caspases, as recently reviewed (Bell and Megeney, 2017; Nakajima and Kuranaga, 2017). These functions include roles in differentiation, such as limiting stemness or promoting axonal regeneration (Dick et al., 2015; Fernando et al., 2002; Fujita et al., 2008; Pinan-Lucarre et al., 2012; Weaver et al., 2014). For instance, in *C. elegans*, we previously reported a non-apoptotic role for the CED-3 caspase in the LIN-28 pluripotency pathway. Inactivation of several key factors, including LIN-14, DISL-2(Dis312) and LIN-28, by CED-3 allows rapid cell fate specification of seam cells in *C. elegans* (Weaver et al., 2014, 2017). Analogous functions in limiting pluripotency have been shown in mammals, with caspase-3 inactivating Nanog in embryonic stem cells (Fujita et al., 2008) and Pax7 in muscle satellite cells (Dick et al.,

2015). In addition, the caspase-3 ortholog, drICE, was shown to be required for sperm differentiation in *Drosophila* (Arama et al., 2003, 2007). Further, CED-3 caspase was recently shown to be necessary for the ability of neuroblasts to divide asymmetrically by size and counter their *pig-1*(MELK)-dependent mitotic potential prior to cell death (Mishra et al., 2018). Based on these and other ongoing studies, it has been suggested that caspases have conserved non-canonical roles in repressing expression of key stem factors to establish asymmetric cell divisions (Bell and Megeney, 2017).

One intriguing question that remains is whether or not caspases have wide-ranging non-apoptotic roles in regulating gene expression during development. The discovery of such global non-canonical roles contributing to cell vigor would redefine the physiological roles for these caspases. Ongoing efforts in *Drosophila* have made use of sophisticated reporter systems to reveal the widespread presence of caspase activities throughout multiple tissues in development (Baena-Lopez et al., 2018; Tang et al., 2015). Exactly what roles these caspases are performing remains to be determined.

We show here that CED-3 caspase acts in opposition to the activity of a p38 MAPK in the absence of stress, to promote larval development in *C. elegans*. Our findings further suggest that this p38 signaling pathway, acting at least partly through the epidermal-specific GATA factor ELT-3, normally primes animals against adverse environmental conditions, such as hyperosmolarity, as well as exposure to pathogens. The balance in gene expression programs between the caspase and p38 directs organismal physiology toward either stress resistance or rapid development. Our results thus reveal an unexpected regulatory paradigm that may be widely used to regulate gene expression and support robust development.

RESULTS

CED-3 Caspase Limits PMK-1(p38 MAPK) Pathway to Promote Larval Development

Using an RNAi enhancer screen to reveal genes that become essential for development when *ced-3* caspase is not functional, we identified the dual specificity phosphatase (DUSP) *vhp-1*, well known for regulating MAPK stress-responsive signaling. When *vhp-1* was knocked down by RNAi in *ced-3(-)* mutants during post-embryonic development, we observed a dramatic delay in larval development and associated larval lethality (Figure 1A). When synchronized first larval stage animals were subjected to *vhp-1*(RNAi), *ced-3(-)* animals did not progress beyond the third larval stage in the same time that allowed wild-type animals fed mock(RNAi) or *vhp-1* (RNAi), as well as *ced-3(-)* animals fed mock(RNAi), to mature into young adults with offspring (Figure 1B; see STAR Methods). Although the *vhp-1(-)* mutant has a reported larval arrest phenotype (Mizuno et al., 2004), reducing *vhp-1* by RNAi caused only a small but significant larval growth delay (Figures 1A and 1B), which is consistent with previous observations (Richardson et al., 2010). The synergistic larval growth delay phenotype was observed with three *ced-3* mutants when treated with *vhp-1*(RNAi). These alleles included the *n717* reference null splice-defective mutation, the *n1286* early stop codon mutation, and the *ok2734* large *ced-3* locus deletion mutation (Figures 1B and S1A). These findings suggest that the delay phenotype is the consequence of loss of both *ced-3* and *vhp-1* functions in post-embryonic development. We also found that loss of either the upstream *ced-3* activator, *ced-4*(*Apaf1*) (Figure S1B), or

ced-3 catalytic activity (Figure S1C) recapitulated the larval delay phenotype when combined with *vhp-1* (RNAi). Together these results support the hypothesis that CED-3 caspase has a physiological role related to VHP-1 and may impact a MAPK stress-responsive signaling pathway.

Because VHP-1 is known to negatively regulate both PMK-1 and KGB-1 and thereby affects the expression of several downstream genes (Figure 1C), we tested the steady-state mRNA levels of known downstream targets of MAPK signaling to reveal which, if any, were altered in *ced-3(-)* mutants. We found that *ced-3(-)* mutants exhibited a significant upregulation of the PMK-1-responsive, epidermally expressed anti-microbial peptide gene, *nlp-29* (Figure 1D). In contrast, *kreg-1* and *kreg-2*, regulated by KGB-1, and *F08G5.6*, an intestinally expressed target of PMK-1, were not significantly altered at the mRNA level in *ced-3(-)* mutants (Figure S1D). These results suggested that CED-3 caspase likely limits the epidermal branch of p38 stress-responsive signaling.

We then reasoned that if PMK-1 is a common downstream target for the CED-3 caspase and the VHP-1 phosphatase and if the synergistic developmental delay was due to dysregulation of PMK-1 during larval development, then loss of *pmk-1* should suppress the synthetic larval delay phenotype of *ced-3(-);vhp-1* (RNAi) animals. Indeed, in a *pmk-1(-) ced-3(-)* double mutant, the larval delay seen with *vhp-1*(RNAi) in *ced-3(-)* animals was partially suppressed and development was significantly restored (Figure 1E). These results are consistent with a model that both CED-3 and VHP-1 act to limit the effects of PMK-1(p38 MAPK) pathway signaling.

Our observations are consistent with previous studies demonstrating that hyperactivation of PMK-1 can have very deleterious consequences on development (Cheesman et al., 2016; Kim et al., 2016b; Pukkila-Worley et al., 2012). The activity of PMK-1 therefore needs to be tightly controlled during development. Based on our findings, we tested whether PMK-1 may have a role in limiting developmental rate in the absence of stress. Notably, we found that loss of *pmk-1* function by either mutation (Figure 1F) or RNAi treatment in wild-type animals (Figures S1E and S1F) resulted in accelerated development. We observed that when the majority of wild-type animals fed normal food or mock(RNAi) were in the fourth larval stage, many *pmk-1(-)* mutant or *pmk-1*(RNAi)-treated animals had reached adulthood. In addition to PMK-1, we found that the upstream MAP2K and MAP3K also functioned to repress the rate of larval development by RNAi treatment of wild-type animals or mutant animals for those genes (Figures S1E–S1G). These data suggest that CED-3 caspase counters a p38 MAPK-dependent pathway function to finely regulate developmental speed in the absence of stress.

Caspase Blocks PMK-1(p38 MAPK)-Dependent Epidermal-Specific Stress-Responsive Program

Two PMK-1-dependent, tissue-specific GATA factors in *C. elegans*, namely ELT-2 in the intestine and ELT-3 in the epidermis, activate gene expression in response to various stressors (Block and Shapira, 2015) (Figure 2A). We reasoned that if CED-3 limits a PMK-1 activity in a tissue-specific manner, then we should expect to see a tissue-specific alteration in the levels of either one of the two PMK-1-dependent GATA factors and/or the established

downstream target genes. We found that *ced-3(-)* mutants had upregulation of total protein levels of ELT-3::GFP but no obvious alteration of ELT-2::GFP protein levels (Figure S2A). Moreover, we found that the ELT-3::GFP signal was retained in epidermal nuclei of *ced-3(-)* mutants in the third larval stage, well beyond the time of its down-regulation when *ced-3* function is intact (Figures 2B and 2C). Further, we found that loss of the *elt-3* function restored larval growth of *ced-3(-)* mutants treated with *vhp-1* (RNAi) to an extent comparable to loss of *pmk-1* function (Figure S2B).

We also examined GFP protein expression from several established transgenes that reflect PMK-1 target genes, namely intestinal *hsp-4* (Richardson et al., 2010; Urano et al., 2002), intestinal *T24B8.5* (Shivers et al., 2009) and epidermal *nlp-29* (Pujol et al., 2008a). We found that GFP protein expression from the *nlp-29p::gfp* reporter was strongly induced when treated with *ced-3(RNAi)* but not *vhp-1(RNAi)* (Figures 2D–2F). The observation we see for *vhp-1* (RNAi) is consistent with previous findings (Zugasti et al., 2016). However, we found that the GFP protein expressed from the *hsp-4p::gfp* and *T24B8.5p::gfp* reporters were induced, predominately in the intestine, by *vhp-1* (RNAi), as previously shown (Richardson et al., 2010), but not by *ced-3(RNAi)* (Figures 2G and 2H). The GFP expressed by the *nlp-29p::gfp* reporter due to *ced-3(RNAi)* was visible only in the epidermis (hypodermis) (Figure 2I). This induction was confirmed for the *ced-3(-)* null (Figure S2C) and *ced-3* catalytic null (G360S) (Figure S2D) mutations.

Notably, *nlp-29* induction during fungal infection is *pmk-1*-dependent (Pujol et al., 2008a, 2008b). We found that loss of *pmk-1* suppressed the *ced-3*-dependent induction of *nlp-29p::gfp* with fewer GFP positive animals whereas *vhp-1* (RNAi) enhanced the *ced-3*-dependent induction with more GFP positive animals (Figure 2J). We also confirmed the roles of factors upstream of PMK-1 for GFP expression from the *nlp-29p::gfp* transgene by showing a significant reduction in the percent of GFP positive animals due to *ced-3(-)* (Figure 2K). Our data suggest that the p38-dependent GATA factor, ELT-3, is responsible for upregulation of *nlp-29p::gfp* mRNA levels. Further, our findings confirmed the requirement for CED-3 to limit induction of the epidermal p38 stress-response pathway during development.

CED-3 Caspase and PMK-1(p38 MAPK) Inversely Regulate the Expression of Multiple Epidermal Pathogen- and Stress-Response Factors

To examine potentially broad effects by CED-3 and p38 in regulating gene expression, we analyzed whole transcriptome steady-state mRNA and whole translome ribosomal associated mRNAs from synchronous third larval stage hermaphrodites (Figures S3A and S3B). Following optimization, we isolated *bona fide* ribosomal protected fragments (RPFs) (Figures S3C and S3D). We collected two biological replicates for wild-type, *ced-3(-)* mutants, and *pmk-1(-)* mutants. The biological replicates for each strain clustered with their respective counterpart and differed from the other strains by multi-dimensional scaling analysis (Figure S3E). We found a strong correlation (nearly 100%) between the transcriptome and translome data sets.

Because *ced-3(-)* and *pmk-1(-)* mutants displayed opposing phenotypes on post-embryonic growth and induction of the *nlp-29* anti-microbial peptide, we focused our expression

analyses on genes that were inversely affected by the caspase and p38 MAPK. We found that CED-3 and PMK-1 had opposing regulation of 313 genes (Figure 3A; Table S1). Gene ontology analyses showed that these genes were enriched for pathogen- and stress-responsive genes from the epidermis that function as part of innate immunity and structural integrity (Figure 3B). As examples, the *nlp-29*, *nlp-30*, and *nlp-31* family of epidermal-specific anti-microbial peptides showed a strong trend toward negative regulation by CED-3 and positive regulation by PMK-1 (Figure S3F). This finding was consistent with our *nlp-29p::gfp* transgene reporter results (Figures 2D and 2I). The NLP-29-31 family has a well-established role in innate immunity (Pujol et al., 2008a, 2008b). Using an in-house class enrichment tool (Zugasti et al., 2016), we also found an over-representation of genes regulating sleep-like lethargus (Table S1), which may contribute to the regulation of the developmental rate we observed (Figure 1). We also analyzed genes both downregulated or both upregulated by *ced-3(-)* and *pmk-1(-)* and found these were enriched for intestinal immune and epithelial molting genes, respectively (Figure S4). We also did not find any alteration of ELT-3 mRNA levels demonstrating the effects of *ced-3(-)* mutation on ELT-3 levels were working at the protein level.

Next, to identify altered translation of highly abundant genes, we used a previously established method to pulse label actively elongating peptides that were then identified with mass spectrometry (Arnold et al., 2014; Schmidt et al., 2009) as outlined in Figure S5A. We found that loss of either *pmk-1* or *ced-3* resulted in increased translation as seen by an increase in gross elongating peptides, whereas loss of *vhp-1(DUSP)* resulted in a minor decrease in translation (Figures 3C–3E and S5B). These results suggest that CED-3 and PMK-1 repress a subset of the translome.

Analyses of the genes and/or proteins in both ribosome profiling (Figure S3) and puromycin labeling methods (Figure S5C) revealed that *fasn-1/FASN-1*, *pod-2/POD-2*, and *hsp-60/HSP-60* were downregulated in *ced-3(-)* mutants. Further, *fasn-1/FASN-1* was consistently up-regulated in *pmk-1(-)* mutants based on the findings of both methods (Figure 3F; Table S2). FASN-1 plays a role in lipid metabolism but has also been shown to have critical roles in regulating *nlp-29* expression (Lee et al., 2010) and stress adaptation (Kim et al., 2016a). In both cases, it was found to also act in concert with POD-2. On the basis of these results, we hypothesized that CED-3 and PMK-1 may have critical but opposing roles in regulating the expression of pathogen response genes.

Induction of *nlp-29* expression in the epidermis has previously been described for stress adaptation and innate immunity (Pujol et al., 2008b). Because *fasn-1* has been shown to work in a p38-independent manner to induce *nlp-29* (Lee et al., 2010) and we found that FASN-1 was a highly abundant gene inversely regulated by CED-3 and p38, we wanted to understand the relationship of *fasn-1* to *ced-3(-)*-induced *nlp-29p::gfp* expression. We found that *nlp-29p::gfp* was induced by *fasn-1* (RNAi) beyond the *ced-3(-)* mutation alone (Mock RNAi) (Figures 3G–3I). Also, the *fasn-1*(RNAi) completely overcame the PMK-1 dependence on *nlp-29p::gfp* expression (Figures 3H and 3I; see Figure 2J). The ability of *fasn-1*(RNAi) to activate *nlp-29* independently of p38 in conjunction with the opposing effects of p38 and CED-3 on expression of *fasn-1* suggests that *fasn-1* may work downstream of p38 function to negatively regulate expression of *nlp-29*.

CED-3 Caspase Cleaves PMK-1(p38 MAPK) to Promote Development

We examined the possibility that the PMK-1(p38 MAPK) protein is a direct cleavage target of CED-3 caspase by using an established *in vitro* cleavage assay (Lee and Xue, 2014; Weaver et al., 2014). We found that CED-3 caspase cleaved PMK-1 at Asp327 but not at neighboring Asp residues (Figure 4A), suggesting that PMK-1 is a candidate cleavage target for CED-3 caspase. Mutation of other Asp residues also did not alter CED-3 cleavage, further supporting specificity of the recognition site (Figure S6).

The Asp327 cleavage site conformed to an Asp-Xxx-Xxx-Asp P4-P1 site where Asp327 is the P1 residue N-terminal to the scissile bond (Figure 4B). Both an Asp327Glu and an Asp327Ala mutations blocked cleavage (Figure 4C). Because the negative charge at this position in MAPKs has recently been shown to be important for function *in vivo* (Taylor et al., 2019), we used the Asp327Glu charge-conservative mutation for our functional studies. We generated a *pmk-1(D327E)* cleavage-resistant mutation *in vivo* in the endogenous *pmk-1* locus using CRISPR-Cas9 mutagenesis. We found that the *pmk-1(D327E)* mutant had a developmental delay comparable to *ced-3(-)* mutants when treated with *vhp-1(RNAi)* (Figure 4D). We also found that the *pmk-1(D327E)* mutant upregulated GFP expression when combined with the *nlp-29p::gfp* transgene to an extent comparable to *ced-3(-)* mutation (Figures 4E and 4F). The fact that *pmk-1(D327E)* phenocopies loss of *ced-3* function in this context strongly suggests that PMK-1 activity is normally limited through cleavage by CED-3. We were unable to determine the effects of *ced-3(-)* on PMK-1 protein levels due to technical limitations.

Cleavage-Resistant PMK-1 Does Not Affect Cells Fated to Die by CED-3

To address the possibility that the perdurance of undead cells in *ced-3(-)* mutants during post-embryonic development is responsible for the phenotypes we observed, we used distinct methods to assay the effects of *pmk-1(D327E)* on *ced-3*-dependent programmed cell death in early and late larval development. Using an established method (Zhou et al., 2001), we counted corpses of dying head cells using the *ced-1(e1735)* background to visualize cell deaths (Figures 5A and 5B). We found that *pmk-1(D327E)* had wild-type levels of corpses in first larval stage animals (Figure 5C). Using another established method (Reddien et al., 2007), we counted the number of undead P9-12 ventral nerve cord cells (VNCs) in young adults (Figures 5D and 5E). We observed that *pmk-1(D327E)* did not result in accumulation of undead VNCs, whereas a mild *ced-3* reduction-of-function allele showed accumulation to a detectable extent (Figure 5F). These findings support that the action of CED-3 caspase on p38 MAPK at Asp327 is non-apoptotic in nature and not indirectly affecting development and gene expression because of the perdurance of undead cells.

PMK-1(p38 MAPK) Stress Priming Function Is Limited by CED-3 Caspase

The fungal pathogen *Drechmeria coniospora* infects nematodes by penetrating the cuticle and epidermis, eliciting expression of the anti-fungal peptide genes *nlp-29* and *nlp-31* that have established roles in the resistance to infection (Couillault et al., 2004; Pujol et al., 2008b). Because CED-3 and p38 inversely control expression of pathogen response genes, including the *nlp-29/31* cluster in the epidermis, we thus tested the extent of *nlp-29p::gfp* induction in animals with and without *Drechmeria* infection. In this assay, the STAT

transcription factor family members *sta-1* and *sta-2* were used as negative and positive controls, respectively, for induction of *nlp-29p::gfp* with *Drechmeria* infection based on the findings of a previous study where *sta-1* is not required for responsiveness but *sta-2* is required (Dierking et al., 2011). We observed a heightened response in infected animals when *ced-3* was reduced by RNAi, consistent with a role for CED-3 in limiting pathogen response (Figure 6A). We also observed an elevated response in *pmk-1(D327E)* mutants at the fourth larval stage (Figure 6B). As a possible explanation for the attenuated *nlp-29p::gfp* response observed for the *ced-3(-)* mutant, we observed numerous *ced-3(-)* animals delayed at the second larval stage with very high *nlp-29p::gfp* expression. The difference between the RNAi versus mutant is likely a reflection of transient versus complete loss of *ced-3* function. Moreover, our original screen revealed that *ced-3* has numerous other non-apoptotic functions during larval development.

We then considered if the CED-3 and PMK-1 stress priming functions are limited to pathogens only. We tested animals for survival with an acute high salt stress on agar plates in the absence of a food source. We decided to assay acute hyperosmolarity stress resistance because it does not involve an extended period to assay and therefore limits an adaptation opportunity. It therefore allowed us to test whether animals were primed for an acute stress prior to experiencing the stress. We observed a two-fold increase in survival time of mid-fourth larval stage animals when *ced-3* was absent or with the cleavage-resistant *pmk-1* mutation (Figure 6C). We observed suppression of the *ced-3(-)* mutant survival effect when combined with *pmk-1(-)* mutation. We also observed that *pmk-1(-)* mutants were most skewed with the median value below the mean, indicating higher sensitivity to the high salt (Figure 6C). Altogether, these findings demonstrate that p38 has a stress-priming function during post-embryonic development and the caspase acts to limit this responsiveness to promote development.

DISCUSSION

Caspase Limits Epidermal p38 Stress Surveillance Function

Previous studies have shown caspases, including CED-3, play a role in stress adaptation (Judy et al., 2013; Yee et al., 2014). The fact that the underlying mechanisms or pathways in those cases are still unclear underscores a potentially complex role for caspases in stress signaling. This complexity is further masked by compensatory regulatory mechanisms. Our findings demonstrate an intriguing role for a caspase in opposing a p38 activity that primes animals in advance of adverse environmental encounters. We showed that loss of *pmk-1*(p38 MAPK) significantly suppresses the larval delay for *ced-3(-);vhp-1(RNAi)* animals (Figure 1E). These data suggest a role for CED-3 in limiting the effects of the PMK-1 pathway in the epidermis during larval stages. Previous studies have already demonstrated that the expression of p38 target genes needs to be tightly regulated and coordinated across tissues during development (Kim et al., 2016b).

Based on our findings, p38 seems to delay development potentially to prime animals for adverse exposure to pathogens or other stressors. By limiting the p38-dependent stress priming program, CED-3 caspase promotes development. Lethality associated with expressing CED-3 from transgenes prevented us from testing its tissue-specific functions

more precisely. Nonetheless, our findings that the CED-3 cleavage-resistant *pmk-1* mutant phenocopied *ced-3(-)* mutants for larval growth and stress resistance phenotypes are consistent with a cell-autonomous function for the cleavage of PMK-1 by CED-3. Moreover, based on the observations that the epidermis was previously shown to be the relevant tissue for a PMK-1-dependent osmolarity stress resistance by *osr-1* (Solomon et al., 2004) as well as PMK-1-dependent *Drechmeria* pathogen resistance (Polanowska et al., 2018), we suggest that *ced-3* caspase likely acts to limit p38 signaling in the epidermis. However, as p38 is not critical to other aspects of osmotic stress adaptation (Pujol et al., 2008b; Rohlffing et al., 2010), *ced-3* functions within the context of a complex and incompletely understood regulatory system. The relationship of *vhp-1* and *ced-3* is likely equally complex because loss of *vhp-1* enhanced expression of intestinal stress-responsive reporters, whereas loss of *ced-3* only enhanced an epidermal stress-responsive reporter. As another layer of complexity, *ced-3* blocks expression of epidermal stress response genes but activates expression of intestinal immune response genes (Figures 3 and S4). It remains an area for continued investigation, how caspase impacts immune and stress signaling at the organismal level. The balance of gene expression programs supporting innate immunity and development may demonstrate an evolutionary trade-off between rapid maturation and durability in harsh environments (Figure 6D), reminiscent of the effect of population density on developmental speed (Ludewig et al., 2017).

Caspase Supports Broad Gene Expression Dynamics

Our previous work revealed specific targets in the LIN-28 pluripotency pathway for the CED-3 caspase in a non-apoptotic function that limited symmetric cell divisions (Weaver et al., 2014). Our current study of the *ced-3* caspase demonstrates a larger role for non-canonical caspase functions in development. These distinct roles suggest the possibility of very diverse non-canonical caspase functions in development and homeostasis.

Genetic redundancy likely masks many significant biological roles of genes like *ced-3* that have been functionally characterized through direct genetic approaches. Revealing roles for CED-3 in supporting homeostasis, in addition to its role in achieving cell death, not only expands the range of biological roles for apoptotic caspases, but also reveals a gene regulatory role that could be widely used to regulate gene expression. This unexpected function seems to be important in changing gene expression programs either in stemness decisions or stress surveillance. In both cases, the caspase facilitates the termination of one program and initiation of another.

STAR★METHODS

LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for reagents may be directed to the Lead Contact Benjamin Weaver (Benjamin.Weaver@UTSouthwestern.edu). Unique and stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Strains and Rationale for Selection—The wild-type (wt) reference strain is N2. The *ced-3(-)* mutants bear either the *ced-3(n717)* allele, the *ced-3(n1286)* allele, or *ced-3(ok2734)* allele. These three *ced-3(-)* mutant strains were chosen based on the following rationale. The *ced-3(n717)* allele was identified in a screen for animals with complete loss of post-embryonic cell deaths and was also found to have semi-dominant suppression of heterozygous *egl-1(n487)* egg-laying defect (Ellis and Horvitz, 1986). Additionally, the *ced-3(n717)* allele is the reference allele for *ced-3* loss-of-function mutants and results in defective mRNA splicing (loss of the splice acceptor site upstream of exon 7) (Shaham et al., 1999). The *ced-3(n1286)* allele was identified in a non-complementation screen for suppression of ectopic neuronal cell death and bears a premature stop codon (W428Opal) (Shaham et al., 1999; Yuan et al., 1993). Non-complementation screens have the power to identify lethal alleles. Additionally, the *ced-3(ok2734)* allele bears a large genomic deletion of the *ced-3* gene including the active site (C. elegans Deletion Mutant Consortium, 2012) and was used to confirm the *vhp-1(RNAi)* genetic interaction (Figure S1A) as was the *ced-3(n2433)* catalytic site null mutant (Shaham et al., 1999) (Figure S1C). The *pmk-1(-)* strain had the *pmk-1(km25)* allele (Mizuno et al., 2004). The *hsp-4::gfp(zcIs4)* reporter strain (Richardson et al., 2010; Urano et al., 2002), the *T24B8.5::gfp(agIs219)* reporter strain (Shivers et al., 2009) and the *nlp-29p::gfp(frls7)* reporter strain (Pujol et al., 2008a) were used as indicated. ELT-2::GFP (OP56) and ELT-3::GFP (OP75) (Sarov et al., 2006) were used where indicated.

METHOD DETAILS

RNAi Treatments—Unless otherwise noted, liquid RNAi and plate RNAi treatments were prepared as previously described (Fraser et al., 2000; Lehner et al., 2006; Timmons et al., 2001). In brief, cultures were grown for 15hr with shaking at 37°C with 150 µg/mL ampicillin. Cultures for plates were then spotted on NGM agar with 1 mM IPTG and 150 µg/mL ampicillin and allowed to grow lawns for several days in the upright position to maintain selection. Alternatively, cultures for liquid RNAi were grown out in 96 well plates, spun down at 1,000 xg, resuspended in complete media (Lehner et al., 2006) and synchronous L1 animals were added to wells (about 20 per well). Unless otherwise noted, strains were added to RNAi plates after synchronization in M9 for 18 hours at 20°C.

Microscopy—Images were taken with either a Leica MZ 16F dissecting scope and a Hamamatsu ORCA-ER C4742-95 digital camera (Figures 1, 2 and 3), a Zeiss Axiozoom V16 dissecting scope with a Zeiss Axiocam 506 mono camera (Figures 4 and 5), a fluorescent microscope with DIC (Nomarski) optics (Zeiss Axioplan 2) with a Zeiss Axiocam MRm (Figure 2), or a Zeiss AxioImager M2 with a Hamamatsu ORCA C13440 camera (Figure 5). All images were taken at the same magnification for the same amount of time for comparisons as indicated in the relevant figure legends.

Reverse Transcription and Quantitative PCR—Total RNA was extracted using TRIzol™ Reagent (Invitrogen, 15596-026) from animals with different genotypes and developmental stages. For cDNA synthesis, 1µg of total RNA was used as input for all samples. The SuperScript™ III Reverse Transcriptase (Invitrogen, 18080-044) and Oligo dT

(Invitrogen, 18418-020) system was used for cDNA synthesis. The Mx3000P system (Agilent Technologies) with ABsolute Blue qPCR SYBR Green Low ROX Mix (Thermo Scientific, AB4323/A) was used for qPCR analysis. Each condition was tested with 4 technical replicates and 3 biological replicates in 20 μ L reactions. *rpl-4* was used as the reference gene for normalization in all experiments. Oligos P1-P12 were used for qRT-PCR analyses (Table S3).

Assays for Development—For liquid culture, unless specified otherwise in the figure legends, animals were scored for developmental stages after 48 hr at 20°C following addition of synchronous first larval stage animals on the indicated food source as previously established (Weaver et al., 2014). To obtain gravid adults, mixed populations were maintained on 60 mm NGM plates seeded with OP50 *E. coli* lawns at 20°C. For liquid cultures, gravid adults were treated with alkaline hypochlorite solution (1% sodium hypochlorite and 500 mM sodium hydroxide in water) to obtain eggs that were washed four times in M9 salt solution and incubated at 20°C overnight for hatching. Synchronous L1 animals were then placed on indicated food sources. For solid media, gravid young adults were allowed to lay eggs for 3 hours and removed. Animals were incubated at 20°C and staged at the indicated time intervals. Prior to testing, animals were maintained under stress-free conditions at 20°C for multiple generations, including no starvation, and no obvious contaminations.

Preparation of L3 Larval Stage Samples for RNA Sequencing—Ribosome profiling was done with two biological replicates that were independently generated, collected and processed. Synchronized day 1 young adult wild type (N2), *ced-3(n717)* and *pmk-1(km25)* worms were bleached and then the eggs were incubated in M9 for 24 hours to obtain synchronized L1s. L1s were plated on OP50 for 18hrs at 20°C until >90% of wild type worms reached L3 stage (Figure S3B).

Isolation of Ribosomal Protected Fragments and Total mRNA—The ribosomal profiling protocol was modified based on a published protocol (Aeschmann et al., 2015) and the TruSeq® Ribo Profile Protocol (Illumina). For our method, L3 staged worms were washed off plates, counted and collected in M9. About 165,000 L3 worms per strain were used for one Ribosome Profiling experiment. Worms were washed 2 more times in 10mL of M9 with a final wash was done in 10mL Buffer A (20mM Tris-Hcl pH7.9, 140mM KCl, 1.5mM MgCl₂, 0.5% (v/v) NP-40). After washing, centrifugation and aspirating the buffer, the worm pellet was flash frozen in liquid nitrogen. Frozen pellet was then thawed on ice for 5min before adding 300mL of Assay Buffer (20mM Tris-Hcl pH7.9, 140mM KCl, 1.5mM MgCl₂, 0.5% (v/v) NP-40, 2% (w/v) polyoxyethylene-10-tridecylether, 1%(w/v) sodiumdeoxycholate monohydrate, 1mM DTT, 0.1mM cycloheximide). Worms thawed in the Assay Buffer were then added in drops into a mortar that was pre-cooled with liquid N₂. Using pre-cooled pestle, worm pellets were crushed and grinded into fine powder. After thawing in the mortar, lysate was transferred into 1.5mL tube and centrifuged for 800xg for 3min followed by 12,000xg for 8min. The supernatant was transferred to a fresh tube and A260 was measured at 1:100 dilution. For each genotype, two A260 units of RNA in 100 μ L volume were used with 50 units of RNaseI (Ambion, AM2294) in digestion at room

temperature with shaking at 250 rpm for 45 minutes. 5 μ L of SUPERase-In RNase Inhibitor (Ambion, AM2694) was used to stop the reaction. The RNA Clean & Concentrator-25 Kit (Zymo Research, R1017) was used to purify both the ribosomal protected fragments (RPFs), after RNase digestion, and total RNA. 10 μ g of RNA were then treated with DNase I (NEB, M0303S) at 37°C for 10min, followed by purification with RNA Clean & Concentrator-25 Kit (Zymo Research, R1013). Total RNA was then rRNA depleted with Ribo-Zero Gold rRNA Removal Kit (Illumina, MRZG12324) and purified with RNA Clean & Concentrator-5 Kit (Zymo Research, R1015). RPFs were then purified with 15% TBE Urea gel (Invitrogen, Novex™ EC6885BOX) (Figure S3). 2830 nt fragments (RPFs) were cut, eluted and purified according to Illumina TruSeq® Ribo Profile Protocol.

RNA Library Preparation and Sequencing—The 3' adaptor ligation, reverse transcription, gel purification, cDNA circularization and PCR amplification steps were performed according to the Illumina TruSeq® Ribo Profile Protocol.

For final PCR amplification of library, circular cDNA for total mRNA input was 1 μ L and circular cDNA input for RPF was 5 μ L.

The average fragment size of the libraries was determined using the High Sensitivity D1000 screentape (Agilent, 5067-5584) on a TapeStation 2200 system (Agilent, G2964A). Library sizes ranged between 158-179bp, consistent with ribosomal profiling libraries. Individual library concentrations were determined by qPCR using the KAPA library quantification kit (KAPA, KK4824). Sequencing libraries were pooled together in equal molar quantities. The final library pool had an average size of 166bp and the final pool concentration was determined to be 2.22nM by using the Qubit 3 fluorometer (Invitrogen). Libraries were sequenced on the Illumina Next-Seq 500 (SN: NB501447) at 1.7pM with 1% phiX control (Illumina, FC-110-3001). Paired-end 37 bp reads were obtained using a Next-seq 500/550 High Output 75-cycle sequencing kit v2 (Illumina).

RNA Sequencing Data Analyses—RNA-seq and ribosomal profiling data were processed with the following workflow. Adaptors were removed using SeqPurge (Sturm et al., 2016). rRNA reads were removed using bowtie2 (Langmead and Salzberg, 2012). Reads were mapped to the *C. elegans* genome using STAR (Dobin et al., 2013) allowing only uniquely mapped reads. Mapped reads were counted using HTSeq (Anders et al., 2015) and gene expression profile was analyzed using edgeR (Robinson et al., 2010). Gene set enrichment was done with the Wormbase Enrichment Tool (Angeles-Albores et al., 2016).

Puromycin Labeling and Mass Spectrometry—Puromycin pulse labeling was done in multiple biological replicates that were independently generated, collected and processed. Mass spectrometry ID was performed on two independent biological replicates with 6 conditions in each replicate. Synchronized day 1 young adult wild type (N2), *ced-3(n717)* and *pmk-1(km25)* worms were bleached and eggs were incubated in M9 for 24 hours to obtain synchronized L1s. L1s were plated on OP50 for 18hrs at 20°C until >90% wild type reach L3 stage (Figure S5C). L3 stage worms were transferred onto plates with OP50 supplemented with 0.5mg/mL puromycin. Worms were pulse labeled for 4 hrs at 20°C.

After labeling, worms were harvested by washing off the plates using M9 and rinsing 3 times with M9 to remove bacteria and the pellets were flash frozen in liquid N₂.

The frozen pellet was then sonicated into lysis buffer (50mM Tris PH 8.0, 150mM NaCl, 1% NP-40, 0.2% SDS, 0.5% deoxycholate and 1x Halt Protease inhibitor). Sonication was performed using Branson SFX150 Cell disruptor (Branson Ultrasonics) with 5 times 6 sec pulse at 50% Amp. Lysates were centrifuged at 10,000xg for 1min and then protein concentration of the supernatant was determined using BCA assay (Thermo Scientific 23227). Immunoprecipitation was performed at 4°C for 4 hours. Lysate concentration was at 1.5µg/µL with 750µg total protein for each condition. Each sample was adjusted to the same volume and protein concentration prior to immunoprecipitation. Puromycin antibody was used at 5ug per sample. Pierce MS-Compatible Magnetic IP Kit (Protein A/G) (Thermo Scientific, 90409) was used for pulling down puromycin antibody labeled proteins and subsequent elution step. For each sample, 30µL of beads was incubated with lysate containing antibody bound protein at room temperature for 1 hr followed by washing 3 times with wash buffer (50mM Tris PH 8.0, 150mM NaCl) and eluting with 50µL elution buffer provided by the kit.

Samples from immunoprecipitation were resuspended in 0.1-M ammonium bicarbonate (ABC), 0.1% sodium deoxycholate, reduced and alkylated using 5 mM TCEP/20 mM chloroacetamide at 70°C for 15 min in the dark. Samples were, then trypsinized with 0.25 µg of sequencing grade modified trypsin (Promega) at 42°C for 4 hours. Sodium deoxycholate was removed by phase-transfer toethylacetate. Tryptic peptides were desalted using in-house StageTips with 3M Empore SDB-RPS membrane, and dried using vacuum centrifugation. The peptides were reconstituted in 15 µL of Buffer A (0.1% formic acid in water), of which 5 µL was subjected to LC-MS/MS analysis.

Tryptic peptides were resolved using a Waters nanoACQUITY UPLC system in a single pump trap mode. The peptides were loaded onto a nanoACQUITY 2G-V/MTrap 5µm Symmetry C18 column (180 µm × 20 mm) with 99.5% Buffer A and 0.5% Buffer B (0.1% formic acid in acetonitrile) at 15 µL/min for 3 min. The trapped peptides were eluted and resolved on a BEH C18 column (130 Å, 1.7 µm × 75 µm × 250 mm) using gradients of 3 to 5% buffer B (0-3 min) and 8 to 28% buffer B (3-185 min) at 0.3 µL/min. MS/MS was performed on a LTQ Orbitrap Velos mass spectrometer, scanning precursor ions between 300 and 1800 m/z (1 × 10⁶ ions, 60,000 resolution) and selecting the 20 most intense ions for MS/MS with 180s dynamic exclusion, 10 ppm exclusion width, repeat count = 1, and 30 s repeat duration. Ions with unassigned charge state and MH+1 were excluded from the MS/MS. Maximal ion injection times were 500 ms for FT (one microscan) and 250 ms for LTQ, and the AGC was 1 × 10⁴. The normalized collision energy was 35% with activation Q 0.25 for 10 ms.

MaxQuant/Andromeda (version 1.5.2.8) was used to process raw files from LTQ-orbitrap, and search the peak lists against protein databases consisting of the UniProt *C.elegans* proteome (total 27,124 entries, downloaded at 7/20/2018). The search allowed trypsin specificity with maximum two missed-cleavages, and carbamidomethyl modifications of cysteines were set as fixed whereas protein N-terminal acetylation and oxidation of

methionine were set as variable. MaxQuant used 4.5 ppm main search tolerance for precursor ions, 0.5 Da MS/MS match tolerance, searching top 8 peaks per 100 Da. False discovery rates for both protein and peptide were 0.01 with minimum seven amino acid peptide length. A label-free quantification was enabled with minimum 2 LFQ ratio counts and a fast LFQ option.

***In Vitro* Caspase Cleavage Assay**—CED-3 cleavage reactions were performed using previously established conditions (Lee and Xue, 2014; Weaver et al., 2014, 2017) with the following modifications. In brief, 35S-labeled substrates were synthesized fresh before cleavage reactions using coupled transcription-translation system (Promega). Point mutations were generated using Q5 mutagenesis kit (NEB) and sequence verified. Substrates were freshly synthesized using Easy Tag 35S (PerkinElmer) for 1 hour. 10 μ L cleavage reactions were set up with 1 μ L of resulting substrate, 0.2 μ L of purified CED-3, 25 mM Tris-HCl pH8.0, 0.25 mM EDTA, 0.25 mM sucrose, and 2.5% glycerol for 2 to 4 hours at 30°C and stopped by adding 3 volumes of 2x Laemmli sample buffer and heating to 85°C. Samples were resolved by SDS-PAGE on 4-16% gradient gels and dried before imaging.

CRISPR Mutagenesis—We generated the *pmk-1(D327E)* mutation in the endogenous *pmk-1* locus using established reagents for CRISPR/Cas9 mutagenesis in *C. elegans* (Dickinson et al., 2013; Paix et al., 2014). Briefly, an sgRNA with the gatttgaatgatgtaa spacer was generated from pDD162 as prescribed (Dickinson et al., 2013). The resulting sgRNA vector (pDD162_C768, Key Resources Table) was combined with a rescue oligo bearing the D327E mutation and synonymous mutations (capitalized) for the spacer sequence (ctatggagcatgaa-tatctggctgcttatcaccgatgaaactgaGgagccGattgcagaagaatggatttgaatgatgaCgtCCgTgcagatacaattgatgaatggaagaaattatttggg). Resulting mutants were sequence-confirmed and outcrossed two times before analyses.

Cell Death Assays—A previously established assay (Zhou et al., 2001) for *ced-3*-dependent programmed cell death was used to measure extent of cell death in early first larval stage by counting head corpses visualized in the *ced-1(e1735)* background with Nomarski optics. In brief, early L1 stage larvae just hatched from tri-fold stage embryos were scored for number of head corpses through focal planes. Midplane images were taken for representative animals. A previously established assay (Reddien et al., 2007) for *ced-3*-dependent programmed cell death was used to measure the extent of cell death in late larval stage. Briefly, first day adults were picked using a non-fluorescent microscope and then scored using a fluorescence dissecting scope for number of undead P9-12 ventral nerve cord cells visualized by the *lin-11p::GFP* reporter.

***Drechmeria coniospora* Infection and Assay for *nlp-29p::gfp* Induction**—Eggs prepared by the standard bleach method were allowed to hatch in 50 mM NaCl in the absence of food at 25 °C. Synchronized L1 larvae were transferred to RNAi plates, and cultured at 25 °C until the young adult stage (44 hours). Worms were then infected with *Drechmeria coniospora* and cultured at 25 °C before being analyzed with the COPAS Biosort after 7 or 24 hours.

Hyperosmolarity Assay—Mid-fourth larval stage animals with obvious Christmas stage vulva were placed on high salt NGM agar plates (600 mM NaCl final concentration) without food and scored for survival time. Animals were scored as dead based on the absence of both crawling and pharyngeal pumping.

***Drechmeria coniospora* Infection and Survival Assay**—Infection and survival assays were conducted based on a previously described protocol (Polanowska et al., 2018). Briefly, synchronized L1 larvae were cultured on OP50 plates at 25°C until L4 stage and then infected with *D. coniospora* for 24 h. Groups of 25 worms were then transferred to wells in 12-well plates (4 wells per condition), and images of each well collected automatically at regular intervals (roughly every 20 minutes). The images were examined, and worms scored as dead when they no longer showed sign of any movement between successive images.

QUANTIFICATION AND STATISTICAL ANALYSIS

Quantification methods, statistical tests, sample sizes, and *p* values were reported throughout the study and detailed in figure legends.

DATA AND CODE AVAILABILITY

RNA-seq and ribosome profiling sequence data were deposited in the GEO database (<https://www.ncbi.nlm.nih.gov/geo/>) under accession number GSE145983. All software analyses were done with open source code as indicated in Key Resources Table.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

We thank D. Xue and the CGC (funded by NIH Office of Research Infrastructure Programs [P40OD010440]) for materials; D. Xue, W. Wood, A. Sewell, N. Pujol, M. Cobb, Han lab members, and Weaver lab members for helpful discussions; WormBase and OMIM databases for accessible information; and J. Belougne for worm sorting at the French National Functional Genomics platform, supported by the GIS IBiSA and Labex INFORM. The authors wish to thank T. Lee with the Central Analytical and Mass Spectrometry Laboratory at the University of Colorado Boulder for sample preparation and LC-MS/MS analysis of the samples with equipment purchased using funding from a W.M. Keck Foundation grant. The authors also wish to thank A. Scott and K. Hammond with the University of Colorado BioFrontiers Institute Next-Gen Sequencing Core Facility, which performed the Illumina sequencing. This work is supported in part by a Welch Foundation grant I-2022-20190330 (B.P.W.), National Institutes of Health grant R35GM133755-01 (B.P.W.), National Institutes of Health grant 5R01GM047869 (M.H.), the Howard Hughes Medical Institute (M.H.), the CNRS, INSERM, AMU, and the ANR (ANR-16-CE15-0001-01, ANR-11-LABX-0054, and ANR-11-IDEX-0001-02 to J.J.E.). B.P.W. is the Virginia Murchison Linthicum Scholar in Medical Research at UT Southwestern Medical Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

REFERENCES

- Aeschimann F, Xiong J, Arnold A, Dieterich C, and Großhans H (2015). Transcriptome-wide measurement of ribosomal occupancy by ribosome profiling. *Methods* 85, 75–89. [PubMed: 26102273]
- Anders S, Pyl PT, and Huber W (2015). HTSeq—a Python framework to work with high-throughput sequencing data. *Bioinformatics* 31, 166–169. [PubMed: 25260700]

- Angeles-Albores D, N Lee RY, Chan J, and Sternberg PW (2016). Tissue enrichment analysis for *C. elegans* genomics. *BMC Bioinformatics* 17, 366. [PubMed: 27618863]
- Arama E, Agapite J, and Steller H (2003). Caspase activity and a specific cytochrome C are required for sperm differentiation in *Drosophila*. *Dev. Cell* 4, 687–697. [PubMed: 12737804]
- Arama E, Bader M, Rieckhof GE, and Steller H (2007). A ubiquitin ligase complex regulates caspase activation during sperm differentiation in *Drosophila*. *PLoS Biol.* 5, e251. [PubMed: 17880263]
- Arnold A, Rahman MM, Lee MC, Muehlhaeusser S, Katic I, Gaidatzis D, Hess D, Scheckel C, Wright JE, Stetak A, et al. (2014). Functional characterization of *C. elegans* Y-box-binding proteins reveals tissue-specific functions and a critical role in the formation of polysomes. *Nucleic Acids Res.* 42, 13353–13369. [PubMed: 25378320]
- Baena-Lopez LA, Arthurton L, Bischoff M, Vincent JP, Alexandre C, and McGregor R (2018). Novel initiator caspase reporters uncover previously unknown features of caspase-activating cells. *Development* 745, dev170811.
- Bell RAV, and Megeney LA (2017). Evolution of caspase-mediated cell death and differentiation: twins separated at birth. *Cell Death Differ.* 24, 1359–1368. [PubMed: 28338655]
- Block DH, and Shapira M (2015). GATA transcription factors as tissue-specific master regulators for induced responses. *Worm* 4, e1118607. [PubMed: 27123374]
- C. elegans* Deletion Mutant Consortium (2012). Large-scale screening for targeted knockouts in the *Caenorhabditis elegans* genome. *G3 (Bethesda)* 2, 1415–1425. [PubMed: 23173093]
- Cheesman HK, Feinbaum RL, Thekkiniath J, Downen RH, Conery AL, and Pukkila-Worley R (2016). Aberrant activation of p38 MAP kinase-dependent innate immune responses is toxic to *Caenorhabditis elegans*. *G3 (Bethesda)* 6, 541–549. [PubMed: 26818074]
- Conradt B, and Xue D (2005). Programmed cell death. In *WormBook, The C. elegans Research Community, WormBook*, ed., pp. 1–13, 10.1895/wormbook.1.32.1. <http://www.wormbook.org>.
- Couillault C, Pujol N, Reboul J, Sabatier L, Guichou JF, Kohara Y, and Ewbank JJ (2004). TLR-independent control of innate immunity in *Caenorhabditis elegans* by the TIR domain adaptor protein TIR-1, an ortholog of human SARM. *Nat. Immunol* 5, 488–494. [PubMed: 15048112]
- Crawford ED, and Wells JA (2011). Caspase substrates and cellular remodeling. *Annu. Rev. Biochem* 80, 1055–1087. [PubMed: 21456965]
- Dick SA, Chang NC, Dumont NA, Bell RA, Putinski C, Kawabe Y, Litchfield DW, Rudnicki MA, and Megeney LA (2015). Caspase 3 cleavage of Pax7 inhibits self-renewal of satellite cells. *Proc. Natl. Acad. Sci. USA* 112, E5246–E5252. [PubMed: 26372956]
- Dickinson DJ, Ward JD, Reiner DJ, and Goldstein B (2013). Engineering the *Caenorhabditis elegans* genome using Cas9-triggered homologous recombination. *Nat. Methods* 10, 1028–1034. [PubMed: 23995389]
- Dierking K, Polanowska J, Omi S, Engelmann I, Gut M, Lembo F, Ewbank JJ, and Pujol N (2011). Unusual regulation of a STAT protein by an SLC6 family transporter in *C. elegans* epidermal innate immunity. *Cell Host Microbe* 0, 425–435.
- Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, and Gingeras TR (2013). STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 20, 15–21.
- Ellis HM, and Horvitz HR (1986). Genetic control of programmed cell death in the nematode *C. elegans*. *Cell* 44, 817–829. [PubMed: 3955651]
- Fernando P, Kelly JF, Balazsi K, Slack RS, and Megeney LA (2002). Caspase 3 activity is required for skeletal muscle differentiation. *Proc. Natl. Acad. Sci. USA* 99, 11025–11030. [PubMed: 12177420]
- Fraser AG, Kamath RS, Zipperlen P, Martinez-Campos M, Sohrmann M, and Ahringer J (2000). Functional genomic analysis of *C. elegans* chromosome I by systematic RNA interference. *Nature* 408, 325–330. [PubMed: 11099033]
- Fujita J, Crane AM, Souza MK, Dejosez M, Kyba M, Flavell RA, Thomson JA, and Zwaka TP (2008). Caspase activity mediates the differentiation of embryonic stem cells. *Cell Stem Cell* 2, 595–601. [PubMed: 18522852]
- Judy ME, Nakamura A, Huang A, Grant H, McCurdy H, Weiberth KF, Gao F, Coppola G, Kenyon C, and Kao AW (2013). A shift to organismal stress resistance in programmed cell death mutants. *PLoS Genet.* 9, e1003714. [PubMed: 24068943]

- Kim DH, Liberati NT, Mizuno T, Inoue H, Hisamoto N, Matsumoto K, and Ausubel FM (2004). Integration of *Caenorhabditis elegans* MAPK pathways mediating immunity and stress resistance by MEK-1 MAPK kinase and VHP-1 MAPK phosphatase. *Proc. Natl. Acad. Sci. USA* 101, 10990–10994. [PubMed: 15256594]
- Kim HE, Grant AR, Simic MS, Kohnz RA, Nomura DK, Durieux J, Riera CE, Sanchez M, Kapernick E, Wolff S, and Dillin A (2016a). Lipid biosynthesis coordinates a mitochondrial-to-cytosolic stress response. *Cell* 166, 1539–1552.e16. [PubMed: 27610574]
- Kim KW, Thakur N, Piggott CA, Omi S, Polanowska J, Jin Y, and Pujol N (2016b). Coordinated inhibition of C/EBP by tribbles in multiple tissues is essential for *Caenorhabditis elegans* development. *BMC Biol.* 14, 104. [PubMed: 27927209]
- Langmead B, and Salzberg SL (2012). Fast gapped-read alignment with Bowtie 2. *Nat. Methods* 9, 357–359. [PubMed: 22388286]
- Lee ES, and Xue D (2014). Caspase protocols in *Caenorhabditis elegans*. *Methods Mol. Biol* 1133, 101–108. [PubMed: 24567097]
- Lee KZ, Kniazeva M, Han M, Pujol N, and Ewbank JJ (2010). The fatty acid synthase *fasn-1* acts upstream of WNK and Ste20/GCK-VI kinases to modulate antimicrobial peptide expression in *C. elegans* epidermis. *Virulence* 1, 113–122. [PubMed: 21178429]
- Lehner B, Tischler J, and Fraser AG (2006). RNAi screens in *Caenorhabditis elegans* in a 96-well liquid format and their application to the systematic identification of genetic interactions. *Nat. Protoc* 1, 1617–1620. [PubMed: 17406454]
- Ludewig AH, Gimond C, Judkins JC, Thornton S, Pulido DC, Micikas RJ, Döring F, Antebi A, Braendle C, and Schroeder FC (2017). Larval crowding accelerates *C. elegans* development and reduces lifespan. *PLoS Genet.* 13, e1006717. [PubMed: 28394895]
- Mishra N, Wei H, and Conradt B (2018). *Caenorhabditis elegans* *ced-3* caspase is required for asymmetric divisions that generate cells programmed to die. *Genetics* 210, 983–998. [PubMed: 30194072]
- Mizuno T, Hisamoto N, Terada T, Kondo T, Adachi M, Nishida E, Kim DH, Ausubel FM, and Matsumoto K (2004). The *Caenorhabditis elegans* MAPK phosphatase VHP-1 mediates a novel JNK-like signaling pathway in stress response. *EMBO J.* 23, 2226–2234. [PubMed: 15116070]
- Nakajima YI, and Kuranaga E (2017). Caspase-dependent non-apoptotic processes in development. *Cell Death Differ.* 24, 1422–1430. [PubMed: 28524858]
- Paix A, Wang Y, Smith HE, Lee CY, Calidas D, Lu T, Smith J, Schmidt H, Krause MW, and Seydoux G (2014). Scalable and versatile genome editing using linear DNAs with microhomology to Cas9 sites in *Caenorhabditis elegans*. *Genetics* 198, 1347–1356. [PubMed: 25249454]
- Pinan-Lucarre B, Gabel CV, Reina CP, Hulme SE, Shevkoplyas SS, Slone RD, Xue J, Qiao Y, Weisberg S, Roodhouse K, et al. (2012). The core apoptotic executioner proteins CED-3 and CED-4 promote initiation of neuronal regeneration in *Caenorhabditis elegans*. *PLoS Biol.* 10, e1001331. [PubMed: 22629231]
- Polanowska J, Chen JX, Soulé J, Omi S, Belougne J, Taffoni C, Pujol N, Selbach M, Zugasti O, and Ewbank JJ (2018). Evolutionary plasticity in the innate immune function of Akirin. *PLoS Genet.* 14, e1007494. [PubMed: 30036395]
- Pujol N, Cypowyj S, Ziegler K, Millet A, Astrain A, Goncharov A, Jin Y, Chisholm AD, and Ewbank JJ (2008a). Distinct innate immune responses to infection and wounding in the *C. elegans* epidermis. *Curr. Biol* 18,481–489. [PubMed: 18394898]
- Pujol N, Zugasti O, Wong D, Couillaud C, Kurz CL, Schulenburg H, and Ewbank JJ (2008b). Anti-fungal innate immunity in *C. elegans* is enhanced by evolutionary diversification of antimicrobial peptides. *PLoS Pathog.* 4, e1000105. [PubMed: 18636113]
- Pukkila-Worley R, Feinbaum R, Kirienko NV, Larkins-Ford J, Conery AL, and Ausubel FM (2012). Stimulation of host immune defenses by a small molecule protects *C. elegans* from bacterial infection. *PLoS Genet.* 8, e1002733. [PubMed: 22719261]
- Reddien PW, Andersen EC, Huang MC, and Horvitz HR (2007). DPL-1 DP, LIN-35 Rb and EFL-1 E2F act with the MCD-1 zinc-finger protein to promote programmed cell death in *Caenorhabditis elegans*. *Genetics* 175, 1719–1733. [PubMed: 17237514]

- Richardson CE, Kooistra T, and Kim DH (2010). An essential role for XBP-1 in host protection against immune activation in *C. elegans*. *Nature* 463, 1092–1095. [PubMed: 20182512]
- Robinson MD, McCarthy DJ, and Smyth GK (2010). edgeR: a bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* 26, 139–140. [PubMed: 19910308]
- Rohlfing AK, Miteva Y, Hannenhalli S, and Lamitina T (2010). Genetic and physiological activation of osmosensitive gene expression mimics transcriptional signatures of pathogen infection in *C. elegans*. *PLoS One* 5, e9010. [PubMed: 20126308]
- Sarov M, Schneider S, Pozniakovski A, Roguev A, Ernst S, Zhang Y, Hyman AA, and Stewart AF (2006). A recombineering pipeline for functional genomics applied to *Caenorhabditis elegans*. *Nat. Methods* 3, 839–844. [PubMed: 16990816]
- Schmidt EK, Clavarino G, Ceppi M, and Pierre P (2009). SUnSET, a nonradioactive method to monitor protein synthesis. *Nat. Methods* 6, 275–277. [PubMed: 19305406]
- Shaham S, Reddien PW, Davies B, and Horvitz HR (1999). Mutational analysis of the *Caenorhabditis elegans* cell-death gene *ced-3*. *Genetics* 753, 1655–1671.
- Shivers RP, Kooistra T, Chu SW, Pagano DJ, and Kim DH (2009). Tissue-specific activities of an immune signaling module regulate physiological responses to pathogenic and nutritional bacteria in *C. elegans*. *Cell Host Microbe* 6, 321–330. [PubMed: 19837372]
- Solomon A, Bandhakavi S, Jabbar S, Shah R, Beitel GJ, and Morimoto RI (2004). *Caenorhabditis elegans* OSR-1 regulates behavioral and physiological responses to hyperosmotic environments. *Genetics* 767, 161–170.
- Sturm M, Schroeder C, and Bauer P (2016). SeqPurge: highly-sensitive adapter trimming for paired-end NGS data. *BMC Bioinformatics* 77, 208.
- Tang HL, Tang HM, Fung MC, and Hardwick JM (2015). In vivo CaspaseTracker biosensor system for detecting anastasis and non-apoptotic caspase activity. *Sci. Rep* 5, 9015. [PubMed: 25757939]
- Taylor C.A.t., Cormier KW, Keenan SE, Earnest S, Stippec S, Wichaidit C, Juang YC, Wang J, Shvartsman SY, Goldsmith EJ, and Cobb MH (2019). Functional divergence caused by mutations in an energetic hotspot in ERK2. *Proc. Natl. Acad. Sci. USA* 776, 15514–15523.
- Timmons L, DL C, Court DL, and Fire A (2001). Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in *Caenorhabditis elegans*. *Gene* 263, 103–112. [PubMed: 11223248]
- Urano F, Calfon M, Yoneda T, Yun C, Kiraly M, Clark SG, and Ron D (2002). A survival pathway for *Caenorhabditis elegans* with a blocked unfolded protein response. *J. Cell Biol* 758, 639–646.
- Weaver BP, Weaver YM, Mitani S, and Han M (2017). Coupled caspase and N-end rule ligase activities allow recognition and degradation of pluripotency factor LIN-28 during non-apoptotic development. *Dev. Cell* 47, 665–673.e6.
- Weaver BP, Zabinsky R, Weaver YM, Lee ES, Xue D, and Han M (2014). CED-3 caspase acts with miRNAs to regulate non-apoptotic gene expression dynamics for robust development in *C. elegans*. *eLife* 3, e04265. [PubMed: 25432023]
- Yee C, Yang W, and Hekimi S (2014). The intrinsic apoptosis pathway mediates the pro-longevity response to mitochondrial ROS in *C. elegans*. *Cell* 757, 897–909.
- Yuan J, Shaham S, Ledoux S, Ellis HM, and Horvitz HR (1993). The *C. elegans* cell death gene *ced-3* encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. *Cell* 75, 641–652. [PubMed: 8242740]
- Zhou Z, Hartweg E, and Horvitz HR (2001). CED-1 is a transmembrane receptor that mediates cell corpse engulfment in *C. elegans*. *Cell* 704, 43–56.
- Zugasti O, Thakur N, Belougne J, Squiban B, Kurz CL, Soulé J, Omi S, Tichit L, Pujol N, and Ewbank JJ (2016). A quantitative genome-wide RNAi screen in *C. elegans* for antifungal innate immunity genes. *BMC Biol.* 74, 35.

Highlights

- PMK-1 (p38 MAPK) has a stress surveillance function that limits development
- CED-3 caspase represses PMK-1 by proteolytic cleavage, promoting development
- CED-3 and PMK-1 inversely regulate epidermal stress response factors
- Protein stability, gene expression, and metabolism are coordinated in development




Figure 1. Caspase Represses a Non-Stress p38 MAPK Function that Delays Post-Embryonic Development

(A and B) Loss of both *ced-3* and *vhp-1* functions compromise viability. Images (A) and quantification (B) of worms in liquid RNAi cultures taken on a dissecting scope, showing a synergistic larval delay phenotype in *ced-3(-)* animals treated with *vhp-1*(RNAi). Magnification was the same throughout (scale bar indicates 1.0 mm). Arrows indicate P0 animals delayed in mid larval development. For all conditions, synchronous L1 stage P0 animals were added to the indicated food source (RNAi) and scored for developmental stage when negative control P0 animals had reached adulthood. Images in (A) show obvious presence of offspring (eggs and L1 stage larvae) in control wells. Quantified data are shown as dot plots indicating the percent of original P0 animals in the given well remaining at L3 stage or earlier, with total number of animals scored for each indicated condition. Data are pooled from three independent experiments and each dot corresponds to an individual well (four wells per experiment). Median values (horizontal bars). *Significant for wild-type treated with *vhp-1*(RNAi) compared to mock(RNAi), $p = 0.0037$, Mann-Whitney. **Significant for both *ced-3(-)* strains treated with *vhp-1* (RNAi) compared to both mock(RNAi) of the given strain and wts train treated with *vhp-1*(RNAi), $p < 0.0001$, Mann-

Whitney. For quantification of a *ced-3(-)* mutant generated by another lab, confirmation of *ced-4(Apaf)* requirement, and CED-3 caspase catalytic activity, see Figures S1A–S1C. (C) The VHP-1 phosphatase is known to negatively regulate (black stops) PMK-1(p38 MAPK) and KGB-1 MAPK that activate (arrows) downstream genes (Kim et al., 2004; Richardson et al., 2010).

(D) qRT-PCR analysis demonstrates that CED-3 caspase limits the expression of epidermal PMK-1 downstream target *nlp-29*. *Significant for *ced-3(-)* strain compared to wt, $p = 0.016$, t test, standard deviation shown. Other PMK-1 and KGB-1 targets are not significantly upregulated by *ced-3(-)* mutation (Figure S1D).

(E) Loss of *pmk-1* function helps restore larval development of *ced-3(-)* animals treated with *vhp-1*(RNAi) on agar plates. Data are shown as dot plots with total number of animals scored for each condition. Data are pooled from two independent experiments and each dot corresponds to an individual plate. Median values (thin horizontal bars). A significant restoration of development was observed with *pmk-1(-)* compared to animals with wild-type *pmk-1* function. *Statistical comparisons indicated by brackets, $p < 0.0001$, Mann-Whitney.

(F) Effect of *pmk-1(p38)(-)* mutation alone on larval developmental rate. Wild-type and *pmk-1(-)* strains were assessed for the percent of animals at the fourth larval stage or adult stage 48 h after hatching. Proportion of animals for the given stage with standard deviation is shown, with total number of animals scored for each condition. *Significant, *pmk-1(-)* compared to wild-type, $p < 0.0001$, Fisher's exact test. For confirmation of the PMK-1(p38) pathway and upstream factors in negatively repressing post-embryonic development in the absence of stress, see Figures S1E–S1G.




Figure 2. CED-3 Caspase Limits Expression of a p38-Dependent Anti-Microbial Peptide in the Epidermis

(A) Diagram of the stress-responsive p38 MAPK pathway and tissue-specific GATA transcription factors and transcriptional targets. Dashed arrows indicate downstream targets. (B and C) Pseudo-colored images (B) and quantitation (C) of upregulation of the p38-dependent epidermal-specific GATA transcription factor ELT-3 in the *ced-3(-)* background (see also Figure S2A for western blot analyses of ELT-3 and ELT-2). Arrows indicate epidermal nuclei. Scale bar, 50 μ m. The median of mean gray values is plotted as a function of gonad length to account for fine differences in developmental stage. Dots indicate

individual animals. The *ced-3(-)* strain had significant upregulation compared to wt, $p < 0.005$, Mann-Whitney. Also see Figure S2B for suppression tests with *pmk-1* and *elt-3* mutants.

(D and E) Pseudo-colored images (D) and quantitation (E) of *ced-3(RNAi)* induction of *nlp-29p::gfp* expression. GFP protein expressed from a transgene with *nlp-29* promoter and 5' UTR is induced by *ced-3(RNAi)*, but not by *vhp-1(RNAi)*. Scale bar, 1 mm. Percentage of animals expressing GFP with standard deviation is shown with total number of animals scored for each condition. *Significant, mock (RNAi) versus *ced-3(RNAi)*, $p < 0.0001$, Fisher's exact test. Standard deviation shown.

(F) *nlp-29p::gfp* expression was confirmed by western blot. For additional lanes on right side, see Figure S2C for confirmation of comparable GFP induction by *ced-3(-)* null mutation with same exposure time and see Figure S2D for confirmation of GFP fluorescence by *ced-3(n2433)* caspase active site mutation.

(G and H) Intestinal reporters show upregulation by *vhp-1(RNAi)* but not by *ced-3(RNAi)*. The number of GFP positive animals from the *hsp-4p::GFP* (G) and *T24B8.5p::GFP* (H) transgenes were scored in the blind. L4 larvae were put on the indicated RNAi plates and their L4 or young adult stage offspring were examined. *Significant for *vhp-1(RNAi)* versus either mock (RNAi) or *ced-3(RNAi)*, $p < 0.0001$, Fisher's exact test.

(I) Pseudo-colored GFP fluorescence and DIC microscopy show GFP expression caused by *ced-3(RNAi)* is visible only in the epidermis. L4 animals were put on the indicated RNAi and their L4 or young adult stage offspring were examined. Magnification was the same throughout (scale bar indicates 50 μm). Exposure time was the same throughout for GFP fluorescence (150 ms).

(J) Induction of *nlp-29p::GFP* in *ced-3(-)* mutants was blocked by *pmk-1* (RNAi) and enhanced by *vhp-1(RNAi)*. *Significant, mock (RNAi) versus *pmk-1* (RNAi) and *vhp-1(RNAi)*, $p < 0.001$, Mann-Whitney. Each dot represents a plate. Median values (thin horizontal bars).

(K) Confirmation that upregulation of *nlp-29p::GFP* expression by *ced-3(-)* mutation requires known factors upstream of PMK-1 in p38 epidermal pathway. All phenotypes were scored three times in the blind. *Significant, mock (RNAi) versus *pmk-1(RNAi)*, *nsy-1(RNAi)*, and *tir-1(RNAi)*, $p < 0.05$, Mann-Whitney.




Figure 3. Caspase and p38 Inversely Regulate Expression of Epidermal Stress Resistance Genes Including Fatty Acid Synthase *fasn-1*

(A) Whole transcriptome and ribosome profiling analyses of L3 stage animals identified 313 genes that are inversely regulated by CED-3 and PMK-1 in two independent biological replicates. For ribosome profiling workflow, raw data, and selection of L3 stage, see Figure S3; Table S1; STAR Methods.

(B) Gene enrichment analysis of the 313 inversely regulated genes identified an enrichment for pathogen resistance genes expressed in the epidermis (hypodermis in nematodes). Fold enrichment and significance (output of the $-\log_{10}Q$ function is shown). Also see Figure S4

and Table S1 for enrichment analysis of genes down- and up-regulated in both *ced-3(-)* and *pmk-1(-)* mutants.

(C and D) Western blot of puromycin-labeled peptides from wild type, *ced-3(-)* and *pmk-1(-)*, or respective RNAi as indicated. Duplicates loaded with more protein on left (C) and right (D) sides, respectively removed for simplicity. Also see Figure S5B for additional western blots used in quantitation.

(E) Quantitation of replicates (Figures 3D and S5B) shows that *pmk-1* (RNAi) and *ced-3*(RNAi) each have upregulated global translation. *Significant, mock (RNAi) versus *ced-3*(RNAi) and *pmk-1*(RNAi), $p = 0.0286$, Mann-Whitney. Standard deviation shown.

(F) FASN-1 translation is upregulated in *pmk-1(-)* mutants and downregulated in *ced-3(-)* mutants. Strains were normalized to wild-type expression. FASN-1 was identified by both ribosome profiling and puromycin labeling methods as a highly abundant target inversely regulated by *pmk-1* and *ced-3*. For protein IDs, see Table S2. See Figure S5C and STAR Methods for replicates and details of puromycin-labeled peptides that were immunoprecipitated with an anti-puromycin antibody and analyzed by mass spectrometry.

(G-I) *fasn-1* negatively regulates anti-microbial peptide gene expression likely downstream of *ced-3* and *pmk-1* functions. Pseudo-colored images and quantification of *nlp-29p::gfp* expression. Scale bars, 1.0 mm. (G) GFP protein induction by *fasn-1*(RNAi) is beyond *ced-3(-)* alone (mock(RNAi) and compare to Figure 4 *ced-3(-)* alone with similar pixel intensity). (H) The *fasn-1*(RNAi) overcomes *pmk-1*-dependence of *nlp-29p::gfp* expression (see Figure 2J) suggesting *fasn-1* functions downstream of (or parallel to) *pmk-1* function.

(I) Quantitation of GFP intensity per area. *Significant, *ced-3(-)* mock (RNAi) versus *fasn-1* (RNAi) and *pmk-1(-)* mock (RNAi) versus *fasn-1*(RNAi), $p < 0.001$, Mann-Whitney. Median values (thin horizontal bars).




Figure 4. CED-3 Caspase Targets PMK-1(p38 MAPK) to Promote Development and Limit Expression of Anti-Microbial Peptide

(A–C) *In vitro* cleavage analysis with purified CED-3 caspase identifies D327 of PMK-1 as a CED-3 cleavage site. (A) D327A blocks CED-3 cleavage. (B) DxxD cleavage site (P4–P1) residues in PMK-1. Blue triangle indicates scissile bond between the P1 residue, Asp327 (red D) and the P1' residue, Glu328. (C) D327As as well as D327E mutations abolish caspase cleavage. Red asterisk, main cleavage product. Purple asterisk, cleavage-resistant full-length protein. Also see Figure S6 for additional Asp to Ala mutants that do not block cleavage. (D) *ced-3(-)* animals and *pmk-1(D327E)* animals show equivalent developmental delay when treated with *vhp-1*(RNAi). *Significant, mock (RNAi) versus *vhp-1*(RNAi), $p < 0.001$, Mann-Whitney. Median values (thin horizontal bars).

(E and F) The *pmk-1(D327E)* animals show upregulation of *nlp-29p::gfp* expression equivalent to *ced-3(-)* animals. Pseudo-colored images (E) and quantification (F) of *nlp-29p::gfp* expression. Scale bar, 1mm. *Significant, wt versus *ced-3(-)* and *pmk-1(D327E)*, $p < 0.001$, Mann-Whitney. Each dot corresponds to an animal. Mean with standard deviation shown.




Figure 5. Caspase-Cleavage-Resistant p38 MAPK Does Not Impact CED-3-Dependent Programmed Cell Death in Early or Late Larval Development

(A–C) Early first larval stage animals using *ced-1(e1735)* background to visualize head cell corpses of *ced-3*-dependent cells fated to die. The *ced-3(-)* (A) and *pmk-1(D327E)* (B) effects on accumulation of head corpses were evaluated. Representative images of a given focal plane for the indicated genotypes with head corpses (arrows) from cells fated to die being engulfed by neighboring cell. Scale bar, 20 μ m. (C) Total cell corpses found in heads of first larval stage animals. *Significant, *ced-3(-)* versus wt, $p < 0.001$, Mann-Whitney. (D–F) First day adults using *lin-11p::GFP* to visualize undead ventral nerve cord cells (VNCs). The *ced-3(-)* (D) and *pmk-1(D327E)* (E) effects on undead VNCs were evaluated. Representative images of the indicated genotypes with area of P9-12 dead (no GFP) or undead VNCs (bright GFP) (brackets). Pseudo-colored GFP and transmitted light were overlaid in each image to indicate anatomical position. Insets are digital zoom of the area indicated by brackets. Scale bar, 200 μ m. (F) Summary of animals with indicated number of undead P9-12 cells by counting *lin-11p::GFP* positive VNCs. *Significant, *ced-3(-)* versus wt, $p < 0.001$, Fisher's exact test.




Figure 6. Caspase Limits Diverse p38 MAPK-Dependent Stress Responses

(A and B) Loss of *ced-3* by RNAi and *pmk-1(D327E)* primes infected animals for expression of anti-microbial *nlp-29p::gfp*. Expression of *nlp-29p::gfp* in animals with and without *Drechmeria* infection and indicated RNAi treatments (A) or mutant strains (B). Vertical axis shows the intensity of green animals normalized by size (time of flight, TOF). (A) *Significant, *ced-3*(RNAi) versus *sta-1*(RNAi) before infection, $p < 0.0001$, Mann-Whitney. *Significant, *ced-3*(RNAi) versus *sta-1*(RNAi) after infection, $p < 0.0001$, Mann-Whitney. Median values (thin horizontal bars). (B) *Significant, *pmk-1(D327E)* versus wt before infection, $p < 0.0001$, and *ced-3*(-) versus wt before infection, $p = 0.0068$, Mann-Whitney. **Significant, *pmk-1(D327E)* after infection, $p < 0.0001$, Mann-Whitney. (C) Loss of *ced-3* or loss of CED-3 cleavage site in *pmk-1* primes animals for acute hyperosmolarity stress resistance. *Significant, wt versus *ced-3*(-) and *pmk-1(D327E)*, $p < 0.001$, Mann-Whitney, median values (bars). (D) Diagram of opposed regulation of ~300 genes by caspase and p38 to balance stress responses and rapid development. CED-3 directly blocks the action of p38 by proteolytic cleavage (red bar). By inversely regulating the epidermal stress response (dashed lines),

ced-3 and *pmk-1* fine tune the extent of stress priming. The net outcome (arrow) based on inputs alters the balance of stress response and developmental progression (scale).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Mouse monoclonal anti-GFP (clone JL-8) antibody	Clontech	Cat# 632380; RRID: AB_10013427
Rabbit polyclonal anti-Actin antibody	Sigma-Aldrich	Cat# A2066; RRID: AB_476693
Anti-Puromycin Antibody, clone 12D10	Millipore	Cat# MABE343 RRID: AB_2566826
Anti mouse IgG, HRP linked Antibody	Cell Signaling Technology	Cat#7076S RRID: AB_330924
Anti rabbit IgG, HRP linked Antibody	Cell Signaling Technology	Cat#7074S RRID: AB_2099233
Bacterial and Virus Strains		
<i>C. elegans</i> ORF RNAi library Collection	Dharmacon	Car# RCE1181
OP50 <i>E. coli</i> Strain	Caenorhabditis Genetics Center	OP50
<i>Drechmeria coniospora</i>	J. Ewbank Lab	N/A
Chemicals, Peptides, and Recombinant Proteins		
<i>C. elegans</i> CED-3	Weaver et al., 2014	N/A
TRIzol® Reagent	Thermo Fisher Scientific	Cat#15596026
EasyTag™ L-[35S]-Methionine	PerkinElmer	Cat# NEG709A500UC
Critical Commercial Assays		
ABsolute Blue qPCR SYBR Green Low ROX Mix	Thermo Fisher Scientific	Cat# AB-4322/B
TruSeq Ribo Profile (Mammalian) Library Prep Kit	Illumina	Cat# RPHMR12126
Ribo-Zero Gold rRNA Removal Kit (H/M/R)	Illumina	Cat# MRZG12324
Pierce MS-Compatible Magnetic IP Kit (Protein A/G)	Thermo Scientific	Cat# 90409
SuperScript™ III Reverse Transcriptase	Thermo Fisher Scientific	Cat# 18080044
TnT® Quick Coupled Transcription/Translation System	Promega	Cat# L1170
Deposited Data		
RNA-seq and ribosome profiling data	GEO Database	GSE145983
Experimental Models: Organisms/Strains		
<i>C. elegans</i> : Strain MT1522: <i>ced-3(n717)</i>	Caenorhabditis Genetics Center	WB Strain: MT1522
<i>C. elegans</i> : Strain KU25: <i>pmk-1(km25)</i>	Caenorhabditis Genetics Center	WB Strain: KU25
<i>C. elegans</i> : Strain MT3002: <i>ced-3(n1286)</i>	Caenorhabditis Genetics Center	WB Strain: MT3002
<i>C. elegans</i> : Strain RB2071: <i>ced-3(ok2734)</i>	Caenorhabditis Genetics Center	WB Strain: RB2071
<i>C. elegans</i> : Strain MT2547: <i>ced-4(n1162)</i>	Caenorhabditis Genetics Center	WB Strain: MT2547
<i>C. elegans</i> : Strain MT6347: <i>ced-3(n2433)</i>	Caenorhabditis Genetics Center	WB Strain: MT6347

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<i>C. elegans</i> : Strain KU4:sek-1(km4)	Caenorhabditis Genetics Center	WB Strain: KU4
<i>C. elegans</i> : Strain AU1:sek-1(ag1)	Caenorhabditis Genetics Center	WB Strain: AU1
<i>C. elegans</i> : Strain AU3:nsy-1(ag3)	Caenorhabditis Genetics Center	WB Strain: AU3
<i>C. elegans</i> : Strain MH5935:pmk-1(km25) ced-3(n717)	This Study	MH5935
<i>C. elegans</i> : Strain MH5936:ced-3(n717);frIs7[nlp-29p::gfp]	This Study	MH5936
<i>C. elegans</i> : Strain IG274 frIs7 [nlp-29p::GFP + col-12p::DsRed]	Caenorhabditis Genetics Center	WB Strain: IG274
<i>C. elegans</i> : Strain BPW47 ced-3(n717);vpIs1 [lin-15(+) + elt-3::GFP]	This Study	BPW47
<i>C. elegans</i> : Strain JG5 vpIs1 [lin-15(+) + elt-3::GFP]	Caenorhabditis Genetics Center	WB Strain: JG5
<i>C. elegans</i> : Strain BPW24 pmk-1(miy7 [pmk-1(D327E)]) frIs7 [nlp-29p::GFP + col-12p::DsRed] IV	This Study	BPW24
<i>C. elegans</i> : Strain:BPW45 ced-1(e1735);pmk-1(miy7[pmk-1(D327E)])	This Study	BPW45
<i>C. elegans</i> : Strain: BPW47 ced-1(e1735)	This Study	BPW47
<i>C. elegans</i> : Strain: MT5811 ced-1(e1735) I; ced-3(n717) IV	Caenorhabditis Genetics Center	WB Strain: MT5811
<i>C. elegans</i> : Strain:BPW3 ced-3(n2427) IV; nIs106 [lin-11::GFP + lin-15(+)] X	This Study	BPW3
<i>C. elegans</i> : Strain:BPW49 nIs106 [lin-11::GFP + lin-15(+)] X	This Study	BPW49
<i>C. elegans</i> : Strain: BPW50 ced-3(n717)IV; nIs106 [lin-11::GFP + lin-15(+)] X	This Study	BPW50
<i>C. elegans</i> : Strain: BPW51 pmk-1(miy7 [pmk-1(D327E)])IV; nIs106 [lin-11::GFP + lin-15(+)]X	This Study	BPW51
<i>C. elegans</i> : Strain: SJ4005 zcIs4 [hsp-4::GFP] V.	Caenorhabditis Genetics Center	WB Strain: SJ4005
<i>C. elegans</i> : Strain: AU78 agIs219 [T24B8.5p::GFP::unc-54-3' UTR + ttx-3p::GFP::unc-54-3' UTR] III	Caenorhabditis Genetics Center	WB Strain: AU78
<i>C. elegans</i> : Strain: BPW18 ced-3(n2433);frIs7 [nlp-29p::GFP + col-12p::DsRed] IV	This Study	BPW18
Oligonucleotides		
Primers 1-12	This Study	See Table S3
Recombinant DNA		
pDD162_C743	This Study	dpy-10 sgRNA
pDD162_C768	This Study	pmk-1 sgRNA
pWE592	This Study	pTNT_wt pmk-1
pWE593	This Study	pTNT_pmk-1 D99A
pWE594	This Study	pTNT_pmk-1 D112A
pWE595	This Study	pTNT_pmk-1 D241A
pWE596	This Study	pTNT_pmk-1 D327A
pWE597	This Study	pTNT_pmk-1 D335A
pWE598	This Study	pTNT_pmk-1 D338A
pWE599	This Study	pTNT_pmk-1 D346A
pWE601	This Study	pTNT_pmk-1 D327E
Software and Algorithms		

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Fiji (ImageJ)	http://fiji.sc	Ver 1.50i; RRID: SCR_002285
Graphpad Prism	http://www.graphpad.com/	Ver 6.07; RRID: SCR_002798
WormBase		RRID: SCR_003098
OMIM	http://www.omim.org	RRID: SCR_006437
UniProt	http://www.uniprot.org/	RRID: SCR_002380
SeqPurge	https://github.com/imgag/ngs-bits	N/A
Bowtie 2	http://bowtie-bio.sourceforge.net/bowtie2/index.shtml	RRID: SCR_005476
STAR	https://github.com/alexdobin/STAR	RRID: SCR_015899
HTSeq	https://htseq.readthedocs.io/en/release_0.10.0/	RRID: SCR_005514
edgeR	http://bioconductor.org/packages/release/bioc/html/edgeR.html	RRID: SCR_012802
WormBase Enrichment Analysis	https://wormbase.org/tools/enrichment/tea/tea.cgi	N/A

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript